bioMérieux Introduces GENE-UP® , a New Molecular Diagnostic Solution for Food Pathogen Detection Jointly Developed with Bio...
04 Novembre 2015 - 7:00AM
Business Wire
New generation PCR system benefits from the
combined expertise of bioMérieux, world leader in microbiological
food safety control and of BioFire, reputed for its know-how in
molecular biology
Regulatory News:
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20151103006832/en/
bioMérieux GENE-UP molecular biology
platform Copyright Christian Ganet.
bioMérieux (Paris:BIM), a world leader in the field of
in vitro diagnostics, announces the launch of GENE-UP®, its
new PCR-based molecular diagnostic system for the detection of
microorganisms (bacteria and viruses). This platform enables the
microbiological control of food, raw materials and the production
environment for customers in the agri-food sector. It is currently
available for laboratories in the United States and plans are
underway to introduce it into Europe, Latin America and Asia during
the first half of 2016.
bioMérieux, world leader in clinical microbiology diagnostics
and industrial microbiological control developed GENE-UP® jointly
with BioFire Defense, a U.S. company recognized for its expertise
in PCR-based molecular biology systems and acquired by bioMérieux
in January 2014. This innovative solution considerably simplifies
lab workflow, improving productivity while limiting the risk of
inter-sample contamination.
GENE-UP® is simple to use, featuring a flexible system that
provides laboratory directors and production teams remote access to
lab results, thereby accelerating the decision-making process for
batch release waiting to be shipped.
The GENE-UP® platform menu enables the detection of the most
commonly tested pathogens in the food chain, such as Salmonella,
Escherichia coli O157:H7 and Listeria. This offer will continue to
be expanded in the coming months with additional tests designed to
meet the specific needs of the various agri-food sectors. The
methods used to detect Salmonella and E. coli O157:H7 have already
received AOAC-RI certification (no. 061504 and 061505), which is
recognized in a number of countries, including the United States,
as an indication of a technology’s excellent performance.
In addition, GENE-UP® being an open platform, is ideally suited
to the utilization of tests in the CEERAM product range (CEERAM is
a company specialized in molecular biology acquired by bioMérieux
in December 2014). CEERAM tests detect viruses, including
noroviruses and hepatitis A in the agri-food production chain.
“We are especially proud to provide our customers with a
new-generation molecular biology system that helps them limit
contamination risks more effectively across the entire production
chain, while at the same time addressing their operational needs to
optimize workflows,” said Nicolas Cartier, Corporate Vice President
of bioMérieux’s Industrial Microbiology Unit. “This new platform
resulting from the combination of BioFire’s know-how in molecular
biology and bioMérieux’s expertise in microbiology, further
strengthens our portfolio of tailor-made solutions and is perfectly
adapted to address the diverse needs of the agri-food sector. With
25 years of expertise and a solid leadership position in the
field of industrial microbiological control, this new launch
confirms our commitment to protecting consumers’ health.”
About bioMérieux
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 50
years, bioMérieux is present in more than 150 countries through 42
subsidiaries and a large network of distributors. In 2014, revenues
reached €1,698 million with 88% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments,
software) which determine the source of disease and contamination
to improve patient health and ensure consumer safety. Its products
are used for diagnosing infectious diseases and providing high
medical value results for cancer screening and monitoring and
cardiovascular emergencies. They are also used for detecting
microorganisms in agri-food, pharmaceutical and cosmetic
products.
bioMérieux is listed on the NYSE Euronext Paris stock
market(Symbol: BIM – ISIN: FR0010096479).
Corporate website: www.biomerieux.combioMérieux Industry
website: www.biomerieux-industry.comInvestors website:
www.biomerieux-finance.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151103006832/en/
Investor RelationsbioMérieuxSylvain Morgeau, + 33
(0)4 78 87 22 37investor.relations@biomerieux.comorMedia
RelationsbioMérieuxAurore Sergeant, + 33 4 78 87 54
75media@biomerieux.comorImage SeptLaurence Heilbronn, + 33 1
53 70 74 64lheilbronn@image7.frorClaire Doligez, +33 1 53 70 74
48cdoligez@image7.fr
Biomerieux (EU:BIM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Biomerieux (EU:BIM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024